Eisai subsidiary nabs Japan rights for schizophrenia drug; Novavax’s $50M milestone

Plus, news about Candel, Inovio and RemeGene:

Eisai licenses Newron Pharmaceuticals’ evenamide: Eisai’s subsidiary EA Pharma will pay up to €117 million ($123 million) …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

ACB Stock analysis and is ACB stock a good investment

July 28, 2023

Regenxbio shares new mid-stage data for its wet AMD gene therapy

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 22, 2024

Research reveals transgenerational effects of adversity on the human gut microbiome

Hardship experienced by mothers during their own childhood or during pregnancy is reflected in the composition of their 2-year-old children’s gut microbiomes, reports an international

July 21, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.